This is a multicenter screening study to characterize the prevalence of the KIT D816V mutation in participants with suspected clonal mast cell disease.
Who can participate
Key Inclusion Criteria:
* Cohort 1 participants must meet inclusion criteria for either SMAC-A or SMAC-B:
1\. SMAC-A
* Documented anaphylaxis due to Hymenoptera venom with cardiovascular symptoms or
* Documented anaphylaxis without known trigger(s) or allergen(s) warranting hospitalization, emergency room visit, and/or epinephrine with cardiovascular symptoms 2. SMAC-B
* Episodic or recurrent signs and symptoms consistent with mast cell activation without known triggers or allergens in at least 2 of the following organ systems: skin, respiratory/naso-ocular, gastrointestinal tract, or cardiovascular.
* Any clinical response on one or more optimally dosed therapies intended to mitigate mast cell mediators, as determined by the Investigator.
* Cohort 2 participants must have confirmed, known diagnosis of 1 of the following criteria:
1. Either hypermobile Ehlers-Danlos syndrome or documented history of hypermobility spectrum disorder.
2. Postural orthostatic tachycardia syndrome with one or more systemic symptoms.
3. Early onset (≤50 years old) osteoporosis or osteopenia.
* Cohort 3 participants must have documented diagnosis of 1 of the following, according to World Health Organization 5th edition criteria: chronic myelomonocytic leukemia or myelodysplastic syndrome/myeloproliferative neoplasm not otherwise specified.
Key Exclusion Criteria:
* Participants previously diagnosed with any of the following:
1. Monoclonal mast cell activation syndrome with a known KIT mutation
2. Cutaneous mastocytosis only (that is, no documentation of systemic mast cell disease via bone marrow biopsy)
3. Any subtype of systemic mastocytosis
4. Mast cell sarcoma
* Cohort 2 only: Osteopenia or osteoporosis attributed to known genetic, endocrine, nutritional, or other medical conditions.
Note: Additional protocol-defined criteria apply.
Interventions
Screening
OTHER
Locations
17
United States (17)
Emory University
Atlanta , Georgia
AllerVie Clinical Research
Birmingham , Alabama
O'Neal Comprehensive Cancer Center at the UAB
Birmingham , Alabama
The University of North Carolina at Chapel Hill
Chapel Hill , North Carolina
AIR Care
Dallas , Texas
AllerVie Health
Glenn Dale , Maryland
Somnos Clinical Research
Lincoln , Nebraska
Tulane University School of Medicine
New Orleans , Louisiana
Mount Sinai Hospital
New York , New York
Midwest Allergy Sinus Asthma
Normal , Illinois
Allergy, Asthma & Clinical Research Center
Oklahoma City , Oklahoma
Allergy & Clinical Immunology Associates
Pittsburgh , Pennsylvania
Kaiser Permanente San Diego
San Diego , California
Barnes-Jewish West County Hospital
St Louis , Missouri
Allergy, Asthma, & Immunology Associates of Tampa Bay
Tampa , Florida
Allergy & Asthma Clinical Research of the Bay Area